Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: A case report

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Colomba, Claudia ^a   Rubino, Raffaella ^a   Siracusa, Lucia ^a   Lalicata, Francesco ^a   Trizzino, Marcello ^a   Titone, Lucina ^a   Tolomeo, Manlio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Myelofibrosis; Ruxolitinib; Tuberculosis

Indexed keywords

JANUS KINASE 2; PYRAZOLE DERIVATIVE; RUXOLITINIB; TUBERCULOSTATIC AGENT;

ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; MALE; MYELOID METAPLASIA; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; JANUS KINASE 2; MALE; PRIMARY MYELOFIBROSIS; PYRAZOLES; TUBERCULOSIS;

EID: 84870836370     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-552     Document Type: Article

References (8)

1. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Baxter EJ, Scott LM, Campbell PJ, et al. Lancet 2005 365 9464 1054 1061 15781101
2. A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R, Passamonti F, Buser AS, et al. N Engl J Med 2005 352 17 1779 1790 10.1056/NEJMoa051113 15858187
3. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Tefferi A, Am J Hematol 2011 86 12 1017 1026 10.1002/ajh.22210 22086865
4. US Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with intermediate and high Risk Myelofibrosis. Deisseroth AB, Kaminskas E, Grillo J, Chen W, Saber H, Lu H, Rothmann MD, Brar SS, Wang J, Garnett C, Bullock J, Burke L, Rahman A, Sridhara R, Farrell A, Clin Cancer Res 2012 15 12 3212 3217
5. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G, N Engl J Med 2012 366 9 787 798 10.1056/NEJMoa1110556 22375970
6. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. N Engl J Med 2010 363 12 1117 1127 10.1056/NEJMoa1002028 20843246
7. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ostojic A, Vrhovac R, Verstovsek S, Ther Clin Risk Manag 2012 8 95 103 Epub 2012 Mar 1 22399854
8. Cellular responses to interferon-gamma. Boehm U, Klamp T, Groot M, Howard JC, Annu Rev Immunol 1997 15 749 795 10.1146/annurev.immunol.15.1.749 9143706